| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -19,042 | -18,985 | -18,234 | -40,686 |
| Depreciation expense | 383 | 361 | 349 | 646 |
| Stock-based compensation expense | 2,181 | 3,091 | 3,911 | 7,718 |
| Non-cash operating lease expense | 273 | 265 | 259 | 503 |
| Net amortization of premiums and accretion of discounts on investments | -161 | -130 | 34 | 533 |
| Prepaid expenses and other current assets | -380 | 756 | 223 | -1,169 |
| Accounts payable | -1,202 | 1,281 | -9 | 264 |
| Accrued expenses and other liabilities | NaN | -3,353 | NaN | NaN |
| Accrued expenses and other current liabilities | -506 | NaN | 1,972 | -4,844 |
| Operating lease liabilities | -294 | -280 | -274 | -382 |
| Other assets | NaN | -137 | NaN | NaN |
| Net cash used in operating activities | -20,538 | -15,237 | -12,283 | -36,145 |
| Purchases of investments | 16,859 | 13,257 | 33,190 | 35,284 |
| Proceeds from maturities of investments | 30,000 | 35,000 | 40,000 | 74,500 |
| Purchases of property and equipment | 14 | 219 | 899 | 551 |
| Net cash provided by investing activities | 13,127 | 21,524 | 5,911 | 38,665 |
| Proceeds from exercise of stock options | NaN | 0 | 0 | 1 |
| Payments of tax withholdings related to vesting of restricted stock units | 33 | 192 | 117 | 441 |
| Net cash used in financing activities | -33 | -192 | -117 | -440 |
| Net decrease in cash, cash equivalents, and restricted cash | -7,444 | 6,095 | -6,489 | 2,080 |
| Cash, cash equivalents and restricted cash at beginning of period | 41,702 | 35,607 | 40,016 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 34,258 | 41,702 | 35,607 | NaN |
Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. (ACRV)